3 / 38
Front-line EGFR TKIs vs chemotherapy
Trial
TKI
Chemo
Mutation
mPFS
(TKI vs Chemo), p
PFS HR
(95%CI)
ORR% (TKI vs
Chemo)
≥G3 TKI tox
(%)
IPASS
Gefitinib
Carbo-Taxol
All
9.5 vs 6.3; p<0.001
0.48
(0.36-0.64)
71 vs 47
33
NEJ002
Gefitinib
Carbo-Taxol
L858R, Del19
10.8 vs 5.4; p<0.001
0.30
(0.22-0.41)
74 vs 31
41
WJTOG
3405
Gefitinib
Cis-Doce
L858R, Del19
9.2 vs 6.3; p<0.001
0.49
(0.34-0.71)
62 vs 32
NR
OPTIMAL
Erlotinib
Carbo-Gem L858R, Del19
13.1 vs 4.6; p<0.001
0.16
(0.10-0.26)
83 vs 36
17
EURTAC
Erlotinib
Cis/Carbo-
Doce/Gem
L858R, Del19
9.7 vs 5.2; p<0.001
0.37
(0.25-0.54)
58 vs 15
46
LUX-3
Afatinib
Cis-Pem L858R, Del19
13.6 vs 6.9; p<0.0001
0.47
(0.34-0.65)
56 vs 23
49
LUX-6
Afatinib
Cis-Gem L858R, Del19
11.0 vs 5.6; p<0.0001
0.28
(0.20-0.39)
67 vs 23
36
Mok NEJM (2009), Mitsudomi Lancet Oncol (2010); Maemondo NEJM (2010); Zhou Lancet Oncol (2011); Rossell Lancet Oncol (2012); Sequist JCO (2013); Wu Lancet Oncol (2014); NR, not reported